Inhibition of tetrandrine on epidermal growth factor-induced cell transformation and its signal transduction

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3187-3193

  Nomura, Masaaki ^a   Yamazaki, Rina ^a   Takaya, Makiko ^a   Kikuchi, Minoru ^a   Takahashi Nishioka, Tatsuo ^a   Akiyama, Kiyoshi ^b   Akiyama, Noriko ^b   Moritani, Shuzo ^c   Kobayashi, Shinjiro ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b Awazu Neuropsychiatric Sanatorium   (Japan)

^c FUKUI PREFECTURAL UNIVERSITY   (Japan)

Author keywords

AP 1; Bisbenzylisoquinoline alkaloid; Cell transformation; ERKs; PI3K Akt pathway; Tetrandrine

Indexed keywords

AGAR; ALKALOID; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TETRANDRINE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG ISOLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEPHANIA TETRANDRA; WESTERN BLOTTING;

ALKALOIDS; ANIMALS; BENZYLISOQUINOLINES; CELL LINE; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPIDERMAL GROWTH FACTOR; EPIDERMIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MICE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 35348937134     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Li DH, Zhang O and Zhong YN: Clinical study on long-term therapeutic effect of combined anti-fibrosis drugs on silicosis. Chin J Indus Hygiene Occup Dis 19: 3-6, 2001.
2. Yu XX, Dang JX, Shi L, Gu PF, Xu XH and Kong FZ: Clinical observation of tetrandrine aerosol on the effect of relieving asthma. Zhejiang J Tradit Chin Med 27: 98-99, 1992 (in Chinese).
3. Li D, Lu H, Li X, Quan Q, Li X and Lu W: Calcium channel blockers in cirrhotic patients with portal hypertension. Chin Med J (Engl) 108: 803-808, 1995.
4. Xie QM, Tang HF, Chen JQ and Bian RL: Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. Acta Pharmacol Sin 23: 1107-1113, 2002.
5. Chen YJ: Potential role of tetrandrine in cancer therapy. Acta Pharmacol Sin 23: 1102-1106, 2002.
6. Lai JH: Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases. Acta Pharmacol Sin 23: 1093-1101, 2002.
7. Yasukawa K, Akasu M, Takeuchi M and Takido M: Bisbenzylisoquinoline alkaloids inhibit tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Oncology 50: 137-140, 1993.
8. Ng LT, Chiang LC, Lin YT and Lin CC: Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines. Am J Chin Med 34: 125-135, 2006.
9. Kobayashi S, Kimura I, Fukuta M, Kontani H, Inaba K, Niwa M, Mita S and Kimura M: Inhibitory effects of tetrandrine and related synthetic compounds on angiogenesis in streptozotocin-diabetic rodents. Biol Pharm Bull 22: 360-365, 1999.
10. Kobayashi S, Inaba K, Kimura I and Kimura M: Inhibitory effects of tetrandrine on angiogenesis in adjuvant-induced chronic inflammation and tube formation of vascular endothelial cells. Biol Pharm Bull 21: 346-349, 1998.
11. Fang LH, Zhang YH, Ma JJ, Du GH, Ku BS, Yao HY, Yun YP and Kim TJ: Inhibitory effects of tetrandrine on the serum- and platelet-derived growth factor-BB-induced proliferation of rat aortic smooth muscle cells through inhibition of cell cycle progression, DNA synthesis, ERK1/2 activation and c-fos expression. Atherosclerosis 174: 215-223, 2004.
12. Wu SJ and Ng LT: Tetrandrine inhibits proinflammatory cytokines, INOS and COX-2 expression in human monocytic cells. Biol Pharm Bull 30: 59-62, 2007.
13. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK and Lee SS: Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappaB activation. Mutat Res 480-481: 243-268, 2001.
14. Bode AM and Dong Z: Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 1: 181-188, 2000.
15. Gescher A, Pastorino U, Plummer SM and Manson MM: Suppression of tumour development by substances derived from the diet-mechanisms and clinical implications. Br J Clin Pharmacol 45: 1-12, 1998.
16. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
17. Zhang H, Li YY, Wu XZ: Effect of tetrandrine on LPS-induced NF-kappaB activation in isolated pancreatic acinar cells of rat. World J Gastroenterol 12: 4232-4236, 2006.
18. Chen F, Sun S, Kuhn DC, Lu Y, Gaydos LJ, Shi X and Demers LM: Tetrandrine inhibits signal-induced NF-kappa B activation in rat alveolar macrophages. Biochem Biophys Res Commun 231: 99-102, 1997.
19. Ho LJ, Juan TY, Chao P, Wu WL, Chang DM, Chang SY and Lai JH: Plant alkaloid tetrandrine down-regulates IκBα kinases-IκBα- NF-κB signaling pathway in human peripheral blood T cell. Br J Pharmacol 143: 919-927, 2004.
20. Adderley SR and Fitzgerald D: Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274: 5038-5046, 1999.
21. Peng G, Zhang F, Zhang Q, Wu K, Zhu F and Wu J: Borna disease virus P protein inhibits nitric oxide synthase gene expression in astrocytes. Virology, 2007 [Epub ahead of print].
22. Huang C, Ma WY and Dong Z: Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-I transactivation and transformation in JB6 P+ cells. Mol Cell Biol 16: 6427-6435, 1996.
23. Colburn NH, Former BF, Nelson KA and Yuspa SH: Tumour promoter induces anchorage independence irreversibly. Nature 281: 589-591, 1979.
24. Colburn NH, Wendel E and Srinivas L: Responses of preneoplastic epidermal cells to tumor promoters and growth factors: use of promoter-resistant variants for mechanism studies. J Cell Biochem 18: 261-270, 1982.
25. Bode AM and Dong Z: Cancer prevention by food factors through targeting signal transduction pathways. Nutrition 20: 89-94, 2004.
26. Dong Z, Birrer MJ, Watts RG, Matrisian LM and Colburn NH: Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 91: 609-613, 1994.
27. Bernstein LR and Colburn NH: AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 244: 566-569, 1989.
28. Angel P and Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991.
29. Crawford HC and Matrisian LM: Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 49: 20-37, 1996.
30. Nomura M, He ZW, Koyama I, Ma WY, Miyamoto K-I and Dong Z: Involvement of Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog 38: 25-32, 2003.
31. Nomura M, Ichimatsu D, Moritani S, Koyama I, Dong Z, Yokogawa K and Miyamoto K: Inhibition of epidermal growth factor-induced cell transformation and Akt activation by caffeine. Mol Carcinog 44: 67-76, 2005.
32. Krasilnikov MA: Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) 65: 59-67, 2000.
33. Stambolic V, Mak TW and Woodgett JR: Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 18: 6094-6103, 1999.
34. Brazil DP, Yang ZZ and Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242, 2004.
35. Nomura M, Ma WY, Huang C, Yang CS, Bowden GT, Miyamoto K and Dong Z: Inhibition of ultraviolet B-induced AP-1 activation by the flavins from black tea. Mol Carcinog 28: 148-155, 2000.
36. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA and Dong Z: Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 94: 5826-5830, 1997.
37. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD and Colburn NH: Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17: 3493-3498, 1998.
38. Huang C, Ma WY, Young MR, Colburn N and Dong Z: Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci USA 95: 156-161, 1998.
39. Kyriakis JM, Liu H and Chadee DN: Activation of SAPKs/JNKs and p38s in vitro. In: Methods in Molecular Biology. Seger R (ed.). Humana Press Inc., Totowa, pp. 61-88, 2004.
40. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH and Yancopoulos GD: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65: 663-675, 1991.
41. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J and Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160, 1994.
42. Kyosseva SV: Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59: 201-220, 2004.
43. Rubinfeld H and Seger R: The ERK cascade as a prototype of MAPK signaling pathways. In: Methods in Molecular Biology. Seger R (ed.) Humana Press Inc., Totowa, pp. 1-28, 2004.
44. Nomura M, Kaji A, Ma WY, Zhong S, Liu G, Bowden GT, Miyamoto K-I and Dong Z: Mitogen- and stress-activated protein kinase 1 mediates activation of Akt by ultraviolet B irradiation. J Biol Chem 276: 25558-255567, 2001.
45. Williams DL, Ozment-Skelton T and Li C: Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock 25: 432-439, 2006.